| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Bad debt expense reversal | - | 0 |
| Net cash provided by operating activities | 3,693 | 1,755 |
| Purchase of property and equipment | 318 | 201 |
| Net cash used in investing activities | -318 | -201 |
| Payments made on note payable | 3,400 | 2,500 |
| Series c conversion costs | 13 | 13 |
| Net cash used in financing activities | -3,413 | -2,513 |
| Net decrease in cash and cash equivalents | -38 | -959 |
| Cash and cash equivalents at beginning of period | 1,461 | - |
| Cash and cash equivalents at end of period | 1,423 | - |
INTERPACE BIOSCIENCES, INC. (IDXG)
INTERPACE BIOSCIENCES, INC. (IDXG)